Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin

Autor:	Dermot Neely, D. A. Price, Geoffrey L. Toms, P.T. Donaldson, M. L. Schmid, Margaret F. Bassendine, David Sheridan
Rok vydání:	2009
Předmět:	Apolipoprotein E Adult Male medicine.medical_specialty Very low-density lipoprotein Apolipoprotein B Hepatitis C virus Blood lipids medicine.disease_cause Gastroenterology Antiviral Agents chemistry.chemical_compound Predictive Value of Tests Internal medicine Ribavirin medicine Humans Pharmacology (medical) Apolipoproteins B Retrospective Studies Hepatology biology business.industry Cholesterol nutritional and metabolic diseases Interferon-alpha Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease Treatment Outcome chemistry Immunology Multivariate Analysis biology.protein lipids (amino acids peptides and proteins) Female business Lipoprotein
Zdroj:	Alimentary pharmacologytherapeutics. 29(12)
ISSN:	1365-2036
Popis:	Summary Background Hepatitis C virus (HCV) co-opts very-low-density lipoprotein (VLDL) pathways for replication, secretion and entry into hepatocytes and associates with apolipoprotein B (apoB) in plasma. Each VLDL contains apoB-100 and variable amounts of apolipoproteins E and C, cholesterol and triglycerides. Aim To determine whether baseline lipid levels predicted treatment outcome. Methods Retrospective analysis was performed of 250 chronic hepatitis C (CHC) patients who had received anti-viral agents interferon-alpha and ribavirin; 165 had a sustained virological response (SVR). Pre- and post-treatment nonfasting lipid profiles were measured and non-high-density lipoprotein (non-HDL) cholesterol (i.e. apoB-associated) was calculated. Binary logistic regression analysis assessed factors independently associated with treatment outcome. Results There was an independent association between higher apoB-associated cholesterol (non-HDL-C) and increased odds of SVR (odds ratio 2.09, P = 0.042). In multivariate analysis, non-HDL-C was significantly lower in HCV genotype 3 (g3) than genotype 1 (P = 0.007); this was reversible upon eradication of HCVg3 (pre-treatment non-HDL-C = 2.8 mmol/L, SVR = 3.6 mmol/L, P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41af2aa1229c94d0bd2aab0543244004 https://pubmed.ncbi.nlm.nih.gov/19392865 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.